1
|
Sato M, Endo M, Tomooka K, Kuroda K, Ueda Y, Sato S, Ikemoto Y, Imai Y, Mitsui K, Tanaka A, Sugiyama R, Nakagawa K, Sato Y, Kuribayashi Y, Kitade M, Itakura A, Takeda S, Tanigawa T. Risk Factors for Alcohol Consumption after Starting Assisted Reproductive Technology Treatment among Japanese Women: Japan-Female Employment and Mental Health in Assisted Reproductive Technology (J-FEMA) Study. Int J Environ Res Public Health 2023; 20:7152. [PMID: 38131704 PMCID: PMC10742806 DOI: 10.3390/ijerph20247152] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 11/25/2023] [Accepted: 11/28/2023] [Indexed: 12/23/2023]
Abstract
AIMS To determine the association between drinking habits and social factors among women undergoing assisted reproductive technology (ART) treatment in Japan. METHODS The study participants who provided answers for the questionnaire concerning alcohol consumption were 1017 female patients undergoing ART treatment were enrolled in the Japan-Female Employment and Mental Health in assisted reproductive technology (J-FEMA) study between August and December 2018. Patient characteristics, including demographic, clinical, and socioeconomic status, were assessed using a self-administered questionnaire which was distributed only once during the period, regardless of their first or follow-up examination. We defined current drinkers who drank ≥46 g of ethanol per week as the habitual drinking group. The risk factors for habitual drinking were analyzed using multivariable-adjusted logistic regression. RESULTS The proportion of habitual drinkers was 15.5% in this study population. The multivariable-adjusted odds ratios (95% confidence interval) for habitual drinking were 2.27 (0.99-5.21) for women aged ≥35 years versus those <35 years, 4.26 (1.98-9.16) for women having partners who currently drink compared to those with partners without current drinking, 1.84 (1.08-3.12) for women without a history of childbirth versus those with, and 1.77 (1.00-3.14) for working women compared with those not working. CONCLUSIONS In our study, habitual drinking among women undergoing ART treatment was significantly associated with older age, no history of childbirth, partner's current drinking status, and working.
Collapse
Affiliation(s)
- Mamiko Sato
- Department of Public Health, Juntendo University Graduate School of Medicine, Tokyo 113-0033, Japan
| | - Motoki Endo
- Department of Public Health, Juntendo University Graduate School of Medicine, Tokyo 113-0033, Japan
| | - Kiyohide Tomooka
- Department of Public Health, Juntendo University Graduate School of Medicine, Tokyo 113-0033, Japan
| | - Keiji Kuroda
- Department of Obstetrics and Gynaecology, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan
- Centre for Reproductive Medicine and Endoscopy, Sugiyama Clinic Marunouchi, Tokyo 100-0065, Japan
| | - Yuito Ueda
- Department of Public Health, Juntendo University Graduate School of Medicine, Tokyo 113-0033, Japan
| | - Setsuko Sato
- Department of Public Health, Juntendo University Graduate School of Medicine, Tokyo 113-0033, Japan
| | - Yuko Ikemoto
- Department of Obstetrics and Gynaecology, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan
| | - Yuya Imai
- Department of Public Health, Juntendo University Graduate School of Medicine, Tokyo 113-0033, Japan
| | - Kiyomi Mitsui
- Department of Hygiene, Public Health, and Preventive Medicine, Showa University, Tokyo 142-8555, Japan
| | - Atsushi Tanaka
- Saint Mother Hospital Infertility Clinic, Fukuoka 807-0825, Japan
| | - Rikikazu Sugiyama
- Centre for Reproductive Medicine and Endoscopy, Sugiyama Clinic Marunouchi, Tokyo 100-0065, Japan
- Centre for Reproductive Medicine and Implantation Research, Sugiyama Clinic Shinjuku, Tokyo 116-0023, Japan
| | - Koji Nakagawa
- Centre for Reproductive Medicine and Implantation Research, Sugiyama Clinic Shinjuku, Tokyo 116-0023, Japan
| | | | - Yasushi Kuribayashi
- Centre for Reproductive Medicine and Endoscopy, Sugiyama Clinic Marunouchi, Tokyo 100-0065, Japan
| | - Mari Kitade
- Department of Obstetrics and Gynaecology, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan
| | - Atsuo Itakura
- Department of Obstetrics and Gynaecology, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan
| | - Satoru Takeda
- Department of Obstetrics and Gynaecology, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan
| | - Takeshi Tanigawa
- Department of Public Health, Juntendo University Graduate School of Medicine, Tokyo 113-0033, Japan
| |
Collapse
|
2
|
Sugiarto, Imai Y, Hayashi Y. Synthesis of Water-Soluble Planar Cobalt(II), Nickel(II), and Copper(II) Hydroxo Clusters Using a (1,4,7-Triazacyclononane)cobalt(III) Complex as a Hydrolysis-Terminating Group. Inorg Chem 2023; 62:1845-1854. [PMID: 35749230 DOI: 10.1021/acs.inorgchem.2c01046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
We report on a group of planar cobalt(II), nickel(II), and copper(II) hydroxo clusters that have a definite composition and are water-soluble: [{Co(tacn)(OH)2}6Co7(OH)12](NO3)2(CF3SO3)6·10H2O (1), [{Co(tacn)(OH)2}6Ni7(OH)12](NO3)2(CF3SO3)6·10H2O (2a), [{Co(tacn)(OH)2}6Ni7(OH)12](BNPP)8·6CH3NO2·8H2O [2b; BNPP = bis(p-nitrophenyl)phosphate], [{Co(tacn)(OH)2}12Ni16(OH)26(OH2)2](SO4)4(CF3SO3)10·30H2O (3a), [{Co(tacn)(OH)2}12Ni16(OH)26(OH2)2](SO4)8(CF3SO3)2·44H2O (3b), [{Co(tacn)(OH)2}2Co2(OH)2(OH2)4](SO4)(CF3SO3)2·4H2O (4), [{Co(tacn)(OH)2}2Ni2(OH)2(OH2)4](SO4)(CF3SO3)2·4H2O (5), and [{Co(tacn)(OH)2}4Cu4(OH)6](ClO4)6·5H2O (6), where tacn is 1,4,7-triazacyclononane. The peripheral of each metal hydroxo cluster plane is chemically protected by the coordination of {CoIII(tacn)(OH)2}+ groups to prevent further hydrolysis. These clusters were synthesized by the reaction of an equimolar amount of [Co(tacn)(OH2)3]3+ and cobalt, nickel, or copper salt at pH values in the range of 6.0-12.0. The structure of the cation in compounds 1, 2a or 2b, 4, and 5 is relevant to the surface structure of the cobalt phosphate and nickel borate oxygen-evolution catalysts; in particular, the Co7(OH)12 core in 1. Moreover, the arrangement of M7(OH)12 in 1 and 2a or 2b and Cu4(OH)6 in 6 represents the solid-state structures of the (111) face of the cubic CoO or NiO and the (002) plane of Cu(OH)2, respectively. Extended X-ray absorption fine structure spectra of an aqueous solution of 1, 2a, 4, and 5 exhibit well-resolved peaks at the first and second coordination spheres due to the M-O and M···M distances, respectively; the solution-state bond distances were estimated, and they agreed well with the bond distances in the solid-state structures.
Collapse
Affiliation(s)
- Sugiarto
- Department of Chemistry, Kanazawa University, Kakuma, Kanazawa 920-1192, Japan
| | - Yuya Imai
- Department of Chemistry, Kanazawa University, Kakuma, Kanazawa 920-1192, Japan
| | - Yoshihito Hayashi
- Department of Chemistry, Kanazawa University, Kakuma, Kanazawa 920-1192, Japan
| |
Collapse
|
3
|
Iida S, Nakanishi T, Momose F, Ichishi M, Mizutani K, Matsushima Y, Umaoka A, Kondo M, Habe K, Hirokawa Y, Watanabe M, Iwakura Y, Miyahara Y, Imai Y, Yamanaka K. 356 IL-17A Is the Critical Cytokine for Liver and Spleen Amyloidosis in Inflammatory Skin Disease. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
4
|
Akashi N, Fujita H, Matoba T, Kohro T, Kabutoya T, Imai Y, Kario K, Kiyosue A, Nakayama M, Miyamoto Y, Nakamura T, Tsujita K, Matoba Y, Sato H, Nagai R. Hyperuricemia predicts worse prognosis in patients with chronic coronary syndrome after percutaneous coronary intervention: insights from Japanese real-world database using a storage system. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The relationship between hyperuricemia (HUA) and cardiovascular disease was observed in some epidemiological studies. However, the association between HUA and chronic coronary syndrome (CCS) after percutaneous coronary intervention (PCI) is not fully elucidated.
Purpose
The purpose of this study was to investigate the prognostic impact of HUA in patients with CCS after PCI.
Methods
This study is a retrospective, multicenter, observational study. We developed the Clinical Deep Data Accumulation System (CLIDAS), which consists of 6 university hospitals and the national cardiovascular center in Japan, directly obtains clinical data including patients background, laboratory data, echocardiogram, electrocardiogram, cardiac catheterization report, prescription, and long-term outcome from electronic medical records. A total of 9936 consecutive patients after PCI were analyzed. Of them, 5138 patients with CCS after PCI during April 2013 and March 2019 were analyzed, and divided into HUA group (patients with HUA at baseline, n=1724) and non-HUA group (patients without HUA at baseline, n=3414). HUA was defined as a serum uric acid levels ≥7.0 mg/dL for men or ≥6.0 mg/dL for women and/or taking urate-lowering drugs. The primary outcome was the major cardiovascular events (MACE) defined as being the composite of cardiovascular death, myocardial infarction, and hospitalization for heart failure.
Results
The median follow-up duration was 910 days (interquartile range: 307–1479 days). The proportion of male (78% vs. 78%) and age (71±11 vs. 71±10) were similar between the HUA and the non-HUA groups. The prevalence of hypertension (87% vs. 82%), atrial fibrillation (9% vs. 5%), and history of previous hospitalization for heart failure (15% vs. 6%) and baseline creatinine value (1.8±2.3 vs. 1.5±2.0 mg/dL) were significantly higher in the HUA group. In contrast, the prevalence of diabetes (43% vs. 48%) was significantly lower in the HUA group. The incidence of MACE was significantly higher in the HUA group than in the non-HUA group (13.1% vs. 6.4%, log rank P<0.001). Multivariate Cox regression analyses revealed that hyperuricemia was significantly associated with MACE (hazard ratio 1.50, 95% confidence interval 1.22–1.84, P<0.001) after controlling for other cardiovascular risk factors.
Conclusion
The real-world database CLIDAS revealed that hyperuricemia was significantly associated with the increase of MACE in patients with CCS after PCI. This result sheds light on the significant role of urate in prediction of prognosis, suggesting the possibility of new therapeutic approaches using urate-lowering drugs or SGLT2 inhibitors for the CCS patients.
Funding Acknowledgement
Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Jichi Medical University, Tochigi, Japan, and Kowa Co., Ltd
Collapse
Affiliation(s)
- N Akashi
- Jichi Medical University Saitama Medical Center , Saitama , Japan
| | - H Fujita
- Jichi Medical University Saitama Medical Center , Saitama , Japan
| | - T Matoba
- Kyushu University Graduate School of Medical Sciences, Cardiovascular Medicine , Fukuoka , Japan
| | - T Kohro
- Jichi Medical University, Clinical Informatics , Tochigi , Japan
| | - T Kabutoya
- Jichi Medical University, Cardiovascular Medicine , Tochigi , Japan
| | - Y Imai
- Jichi Medical University, Clinical Pharmacology , Tochigi , Japan
| | - K Kario
- Jichi Medical University, Cardiovascular Medicine , Tochigi , Japan
| | - A Kiyosue
- University of Tokyo Hospital, Cardiovascular Medicine , Tokyo , Japan
| | - M Nakayama
- Tohoku University Graduate School of Medicine, Medical Informatics , Sendai , Japan
| | - Y Miyamoto
- National Cerebral and Cardiovascular Center Hospital, Open Innovation Center , Osaka , Japan
| | - T Nakamura
- Kumamoto University Hospital, Medical Informatics , Kumamoto , Japan
| | - K Tsujita
- Kumamoto University Hospital, Cardiovascular Medicine , Kumamoto , Japan
| | | | - H Sato
- Precision , Tokyo , Japan
| | - R Nagai
- Jichi Medical University , Tochigi , Japan
| |
Collapse
|
5
|
Jakob R, Kaur H, Marzinek J, Green R, Imai Y, Bolla J, Agustoni E, Robinson C, Bond P, Lewis K, Maier T, Hiller S. The antibiotic darobactin mimics a β-strand to inhibit outer membrane insertase. Acta Cryst Sect A 2022. [DOI: 10.1107/s205327332209619x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
|
6
|
Nagano K, Imai Y, Ukyo Y, Kobayashi T, Yokoyama S. Early phase partial Mayo score following golimumab treatment is associated with endoscopic improvement at 1-year in ulcerative colitis; A post hoc analysis of PURSUIT-J randomized controlled trial. Inflamm Intest Dis 2022; 7:155-162. [PMID: 37064537 PMCID: PMC10091011 DOI: 10.1159/000526264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2021] [Accepted: 06/13/2022] [Indexed: 11/19/2022] Open
Abstract
Objective: Golimumab (GLM) is an anti-tumor necrosis factor-alpha antibody therapy for moderately to severely active ulcerative colitis (UC). Endoscopic improvement is considered one of UC treatment's main goals, and earlier prediction of future endosopic improvement has clinical implications. We retrospectively analyzed data from the PURSUIT-J, a phase III randomized controlled trial evaluating the efficacy of GLM in the maintenance phase, to find predictors for endoscopic improvement after 60 weeks of GLM treatment.
Methods: Ninety-two patients who had completed the maintenance phase of the PURSUIT-J were divided into two groups: those with Mucosal healing (MHs : Mayo endoscopic subscore of 0 or 1) and those without MH at week 60 (non-MHs). Multivariate logistic regression analysis was conducted using baseline data in the induction phase to determine predictive factors for MHs compared to non-MHs.
Results: Twenty-nine patients were classified as MHs and 63 as non-MHs. The multivariate logistic regression analysis showed that the odds ratio for partial Mayo (pMayo) score was highest in MHs (1.87 [95% CI 1.18–2.98]) at baseline in the induction phase. The receiver operating characteristic analysis to determine the timing of predictions of MHs using pMayo showed that an area under the curve reached 0.8 at week 14 after the first GLM administration.
Conclusions: pMayo scores at week 14 of GLM treatment are associated with MH at week 60. These results suggest the timing of when a clinical decision to continue GLM based on the patient-reported outcomes and the physician’s general assessment could be considered.
Collapse
Affiliation(s)
- Katsumasa Nagano
- Medical Affairs Division, Immunology and Infectious Diseases Department, Janssen Pharmaceutical K.K., Tokyo, Japan
- *Katsumasa Nagano,
| | - Yuya Imai
- Clinical Science Division, Immunology Clinical Development Department, R&D, Janssen Pharmaceutical K.K., Tokyo, Japan
| | - Yoshifumi Ukyo
- Statistics & Decision Sciences Japan, R&D, Janssen Pharmaceutical K.K., Tokyo, Japan
| | - Taku Kobayashi
- Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan
| | - Seiji Yokoyama
- Medical Affairs Division, Immunology and Infectious Diseases Department, Janssen Pharmaceutical K.K., Tokyo, Japan
- **Seiji Yokoyama,
| |
Collapse
|
7
|
Imai Y, Ikeuchi H, Suwa J, Ohishi Y, Watanabe M, Nakasatomi M, Hamatani H, Sakairi T, Kaneko Y, Hiromura K. AB0443 LONG-TERM OUTCOMES OF MULTITARGET THERAPY OF MYCOPHENOLATE MOFETIL AND TACROLIMUS IN LUPUS NEPHRITIS: A SINGLE CENTER RETROSPECTIVE ANALYSIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundRecent studies showed the efficacy of multitarget therapy with mycophenolate mofetil (MMF) and calcineurin inhibitor for induction therapy for lupus nephritis (LN)1. However, long-term outcomes have not been well elucidated.ObjectivesWe retrospectively analyzed the long-term outcomes of multitarget therapy of MMF and tacrolimus.MethodsWe examined 27 LN patients (4 male, 23 female) treated with multitarget therapy for induction therapy between Oct. 2009 and Nov. 2018 in our department. Complete remission (CR) was defined as 1) UPCR<0.5 g/gCr, and 2) serum creatinine (S-Cr) normal or if abnormal, within 15% of baseline; 1) and 2) were observed in 2 consecutive visits. Relapse was defined as UPCR>1.0 g/gCr or intensification of immunosuppressive treatment after achievement of CR.ResultsThe mean age was 38.6±11.6 years old. 17 patients were new-onset LN, and 10 patients were relapse LN. UPCR and eGFR before treatment were 4.42±2.98 g/gCr and 71.5±32.9 mL/min/1.73m2, respectively. Renal histology was Class III in 1, III+V in 4, IV in 12. IV+V in 9 and V in 1 by ISN/RPS 2003 classification. CR at 6 and 12 months were 59% and 74%, respectively. Patients were treated by multitarget therapy for median of 25 months (IQR, 5.5-37). Finally, 26 (96%) patients achieved CR. During multitarget therapy, there were 15 serious adverse events: deep vein thrombosis in 2, myocardial infarctions in 2, cervical intraepithelial neoplasia in 2, heart failure in 1, herpes zoster in 1, viral myocarditis in 1, cytomegalovirus gastroenteritis in 1, cholecystitis in 1, pyelonephritis in 1, bacterial enteritis in 1, sepsis in 1, and breast cancer in 1. During the median observation period of 94 months (IQR, 63-111.5) after the initiation of multitarget therapy, 1 patient died due to sudden death. No patient reached end-stage kidney disease or doubling S-Cr. 16 patients relapsed at median of 32 months (IQR,13.8-64.5) after CR; 8 patients relapsed on multitarget therapy, and 8 patients relapsed after cessation of multitarget therapy. Relapse was associated with chronic lesions in renal biopsy and normal or higher C4 levels at treatment initiation by Kaplan Meier analysis (Log-rank, P=0.006, P<0.001, respectively).ConclusionMultitarget therapy effectively induced CR and maintained renal function in long-term period. However, relapse was often observed during or after withdrawal of multitarget therapy.References[1]Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Int Med 2015; 162: 18-26.Disclosure of InterestsYoichi Imai: None declared, Hidekazu Ikeuchi: None declared, Junya Suwa: None declared, Yuko Ohishi: None declared, Mitsuharu Watanabe: None declared, Masao Nakasatomi: None declared, Hiroko Hamatani: None declared, Toru Sakairi: None declared, Yoriaki Kaneko: None declared, Keiju Hiromura Speakers bureau: Chugai, Astellas., Grant/research support from: Chugai, Astellas.
Collapse
|
8
|
Mitsuhashi R, Imai Y, Suzuki T, Hayashi Y. Selective Formation of Intramolecular Hydrogen-Bonding Palladium(II) Complexes with Nucleosides Using Unsymmetrical Tridentate Ligands. Molecules 2022; 27:2098. [PMID: 35408496 PMCID: PMC9000330 DOI: 10.3390/molecules27072098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2022] [Revised: 03/17/2022] [Accepted: 03/21/2022] [Indexed: 12/05/2022] Open
Abstract
Three palladium(II) complexes with amino-amidato-phenolato-type tridentate ligands were synthesized and characterized by 1H NMR spectroscopy and X-ray crystallography. The strategic arrangement of a hydrogen-bond donor and acceptor adjacent to the substitution site of the PdII complex allowed the selective coordination of nucleosides. Among two pyrimidine-nucleosides, cytidine and 5-methyluridine, cytidine was successfully coordinated to the PdII complex while 5-methyluridne was not. On the other hand, both purine-nucleosides, adenosine and guanosine, were coordinated to the PdII complex. As purines have several coordination sites, adenosine afforded three kinds of coordination isomers expected from the three different donors. However, guanosine afforded a sole product according to the ligand design such that the formation of double intramolecular hydrogen-bond strongly induced the specific coordination by N1-position of guanine moiety. Furthermore, the preference of the nucleosides was evaluated by scrambling reactions. It was found that the preference of guanosine is nearly twice as high as adenosine and cytidine, owing to the three-point interaction of a coordination bond and two hydrogen bonds. These results show that the combination of a coordination and hydrogen bonds, which is reminiscent of the Watson-Crick base pairing, is an effective tool for the precise recognition of nucleosides.
Collapse
Affiliation(s)
- Ryoji Mitsuhashi
- Institute of Liberal Arts and Science, Kanazawa University, Kakuma, Kanazawa 920-1192, Ishikawa, Japan
| | - Yuya Imai
- Department of Chemistry, Kanazawa University, Kakuma, Kanazawa 920-1192, Ishikawa, Japan; (Y.I.); (Y.H.)
| | - Takayoshi Suzuki
- Research Institute for Interdisciplinary Science, Okayama University, 3-1-1 Tsushima-naka, Okayama 700-8530, Japan;
| | - Yoshihito Hayashi
- Department of Chemistry, Kanazawa University, Kakuma, Kanazawa 920-1192, Ishikawa, Japan; (Y.I.); (Y.H.)
| |
Collapse
|
9
|
Endo M, Matsui K, Akaho R, Mitsui K, Yan Y, Imai Y, Ueda Y, Muto G, Deshpande GA, Terao Y, Takeda S, Saito M, Hayashi K, Nishimura K, Tanigawa T. Depressive and anxiety symptoms among Japanese cancer survivors: Japan cancer survivorship research project. BMC Cancer 2022; 22:134. [PMID: 35109805 PMCID: PMC8811965 DOI: 10.1186/s12885-022-09215-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2021] [Accepted: 01/19/2022] [Indexed: 01/11/2023] Open
Abstract
BACKGROUND This study aimed to clarify predictors of depressive symptoms and anxiety symptoms after cancer diagnosis among Japanese cancer survivors (CSs). METHODS As part of a Japanese cancer survivorship research project commissioned by the Ministry of Health, Labour and Welfare (MHLW) of Japan, we conducted a web-based nationwide survey of CSs in 2018. We analyzed the risk factors for depressive and anxiety symptoms, as measured by the Hospital Anxiety and Depression Scale Japanese version (HADS). RESULTS Of 1,234 Japanese CSs, mean score of HADS-depression and HADS-anxiety were 4.08 and 4.78, respectively. At the time of the study, the number of CSs with symptoms of depression and anxiety were 111 (9.0%) and 269 (21.8%), respectively. After multivariable analysis, CSs ≥ 60 years old (reference: ≤ 39 years old, odds ratios (OR): 0.39, 95%CI: 0.17-0.90) and those ≥ 10 years from cancer diagnosis (reference: 0-4 years, OR: 0.55, 95%CI: 0.32-0.96) had lower odds for depressive symptoms. And CSs ≥ 60 years old (reference: ≤ 39 years old, OR: 0.27, 95%CI: 0.15-0.49) and those ≥ 10 years from cancer diagnosis (reference: 0-4 years, OR: 0.62, 95%CI: 0.42-0.90) also had lower odds for anxiety symptoms. CSs who received chemotherapy (OR: 1.56, 95%CI: 1.10-2.20) had higher odds for anxiety symptoms. CONCLUSIONS Based on manifestation of symptoms, CSs who were younger, closer to the time of cancer diagnosis, had advanced-staged cancer, or received chemotherapy may be at higher risk for depressive or anxiety symptoms. Those CSs who have higher risk for depression and anxiety symptoms, should be followed-up more carefully for better cancer survivorship, by medical professionals, companies, and society.
Collapse
Affiliation(s)
- Motoki Endo
- Department of Public Health, Juntendo University Faculty of Medicine, Tokyo, Japan.
| | - Kentaro Matsui
- Department of Psychiatry, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.,Department of Clinical Laboratory and Department of Sleep-Wake Disorders, National Center of Neurology and Psychiatry, National Institute of Mental Health, Kodaira, Japan
| | - Rie Akaho
- Department of Psychiatry, Tokyo Women's Medical University School of Medicine, Tokyo, Japan
| | - Kiyomi Mitsui
- Department of Hygiene, Public Health, and Preventive Medicine, Showa University, Tokyo, Japan
| | - Yan Yan
- Department of Palliative Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Yuya Imai
- Department of Public Health, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Yuito Ueda
- Department of Public Health, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Go Muto
- Department of Hygiene, Kitasato University School of Medicine, Kanagawa, Japan
| | - Gautam A Deshpande
- Department of General Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Yasuhisa Terao
- Department of Obstetrics and Gynecology, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Satoru Takeda
- Department of Obstetrics and Gynecology, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Mitsue Saito
- Department of Breast Oncology, Juntendo University School of Medicine, Tokyo, Japan
| | | | - Katsuji Nishimura
- Department of Psychiatry, Tokyo Women's Medical University School of Medicine, Tokyo, Japan
| | - Takeshi Tanigawa
- Department of Public Health, Juntendo University Faculty of Medicine, Tokyo, Japan
| |
Collapse
|
10
|
Nakamura S, Asano T, Tsuchiya H, Sugimoto K, Imai Y, Yokoyama S, Suzuki Y. Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance. Intest Res 2021; 20:329-341. [PMID: 34333910 PMCID: PMC9344245 DOI: 10.5217/ir.2021.00032] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Accepted: 06/07/2021] [Indexed: 11/12/2022] Open
Abstract
Background/Aims Golimumab (GLM) is an anti-tumor necrosis factor-α drug approved for treating moderate-to-severe active ulcerative colitis (UC). A 52-week post-marketing surveillance (PMS) was initiated to evaluate its safety and effectiveness in patients with UC in Japan. We present an interim report of the ongoing PMS. Methods Patients received 200 mg of subcutaneous GLM at week 0, 100 mg at week 2, and 100 mg 4 weekly thereafter. The safety analysis set included 392 patients with UC, and the effectiveness analysis set 387 patients. Safety and effectiveness were assessed at week 6. Results Adverse drug reactions (ADRs) were reported in 8.2% (32/392) and serious ADRs in 4.6% (18/392). The most frequent ADRs were infection and infestation (3.3%), with herpes zoster being the most common. ADRs were significantly higher in patients with concomitant corticosteroid use (odds ratio [OR], 3.45; 95% confidence interval [CI], 1.40–9.68). No significant difference in ADR incidence was observed between patients aged ≥65 and <65 years (OR, 1.23; 95% CI, 0.35–3.47). Six-week effectiveness of GLM was confirmed by a decrease in the partial Mayo score (–2.3; 95% CI, –2.6 to –2.1) and C-reactive protein levels (–0.64; 95% CI, –0.92 to –0.36), including in the biologics-experienced population. Conclusions The safety and effectiveness of GLM at week 6 in a real-world setting were demonstrated in patients with UC in Japan. ADR patterns were consistent with previous reports with no new safety signals. Concomitant corticosteroid use may be associated with increased ADR incidence. The final results of the ongoing PMS are necessary for further evaluation.
Collapse
Affiliation(s)
- Shiro Nakamura
- Department of Internal Medicine II, Osaka Medical College Hospital, Takatsuki, Japan
| | | | | | | | - Yuya Imai
- Janssen Pharmaceutical K.K., Tokyo, Japan
| | | | - Yasuo Suzuki
- Inflammatory Bowel Disease Center, Toho University Sakura Medical Center, Sakura, Japan
| |
Collapse
|
11
|
Kumagai K, Yagi S, Yamaguchi T, Nagashima K, Nomura T, Watanabe M, Makuuchi R, Kawakami K, Otsuka S, Matsushima T, Kadowaki S, Haruta S, Cho H, Yamada T, Kakihara N, Imai Y, Fukunaga H, Saeki Y, Kanaji S, Boku N, Goto M. P-83 The efficacy of chemotherapy for gastric cancer with early recurrence during or after adjuvant S-1. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
12
|
Imai Y, Sakurai M, Nakagawa H, Hirata A, Murakami Y, Kiyohara Y, Ninomiya T, Ishikawa S, Saitoh S, Irie F, Sairenchi T, Kiyama M, Miura K, Ueshima H, Okamura T. Impact of Proteinuria and Low eGFR on Lifetime Risk of Cardiovascular Disease Death: A Pooled Analysis of Data From the Evidence for Cardiovascular Prevention From Observational Cohorts in Japan Study. Eur J Prev Cardiol 2021. [DOI: 10.1093/eurjpc/zwab061.179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): H20–Junkankitou [Seishuu]–Ippan–013; H23–Junkankitou [Seishuu]–Ippan–005; H26-Junkankitou [Seisaku]-Ippan-001; H29–Junkankitou–Ippan–003 and 20FA1002
OnBehalf
EPOCH-JAPAN
Introduction
Absolute risk of Lifetime risk (LTR) is useful estimate for risk communication compared with short term risk or relative risk especially for young people. Proteinuria is leading cause of end-stage kidney disease (ESKD) and independent risk factor for cardiovascular disease (CVD). Although nonproteinuric renal disease is global burden of ESKD, it has been poorly focused. To date, there have been no reports of impact of proteinuria and low eGFR on LTR with the outcome of CVD death in Asian population.
Purpose
We aimed to estimate LTR of CVD death stratified by the status of proteinuria and low eGFR.
Methods
We used modified Kaplan-Meier approach to estimate the remaining lifetime risk of cardiovascular death based on EPOCH-JAPAN(Evidence for Cardiovascular Prevention From Observational Cohorts in Japan) database. LTR was estimated at each index age starting from 40 years for those with proteinuria and without proteinuria stratified by low eGFR, which is defined as eGFR <60 ml/min/1.73 m². Participants were classified into three groups, which were those with proteinuria (Proteinuria (+)), those without proteinuria with low eGFR (Proteinuria (-)/Low eGFR (+)), those without proteinuria without low eGFR (Proteinuria (-)/Low eGFR (-)).
Results
A total of 47,292 participants from 9 cohorts was included in the analysis. Mean follow-up period was 14.6 years with 690,463 person years and total CVD death was 1,075 in men and 1,193 in women. The LTRs at the index age of 40 years were as follows: 17.7% (95% confidence interval: 15.4 – 19.0%) in Proteinuria (-)/Low eGFR (-) group, 26.2% (20.2 – 31.1%) in Proteinuria (-)/low eGFR (+) group, 24.5% (15.1 – 29.3%) in Proteinuria (+) group for men; 15.3%(13.7 – 16.5%), 29.9%(14.7 – 46.8%) , 28.3%(19.4 – 34.7%) for women.
Conclusions
We observed that those without proteinuria with low eGFR have equivalently high LTR with those with proteinuria. These results indicate that even in the absence of proteinuria, low eGFR has high impact on LTR. Lifestyle modification from young age is necessary to prevent from renal dysfunction.
Collapse
Affiliation(s)
- Y Imai
- Keio University School of Medicine, Tokyo, Japan
| | - M Sakurai
- Kanazawa Medical University, Department of Epidemiology and Public Health, Kanazawa, Japan
| | - H Nakagawa
- Kanazawa Medical University, Department of Epidemiology and Public Health, Kanazawa, Japan
| | - A Hirata
- Keio University School of Medicine, Tokyo, Japan
| | - Y Murakami
- Toho University, Department of Medical Statistics, Tokyo, Japan
| | - Y Kiyohara
- Hisayama Research Institute for Lifestyle Disease, Fukuoka, Japan
| | - T Ninomiya
- Kyushu University Graduate School of Medical Sciences, Department of Epidemiology and Public Health, Fukuoka, Japan
| | - S Ishikawa
- Jichi Medical University, Medical Education Center, Tochigi, Japan
| | - S Saitoh
- Sapporo Medical University School of Health Sciences, Department of Nursing, Hokkaido, Japan
| | - F Irie
- Ibaraki Prefectural Office, Department of Health and Welfare, Ibaraki, Japan
| | - T Sairenchi
- Dokkyo Medical University School of Medicine, Department of Public Health, Tochigi, Japan
| | - M Kiyama
- Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
| | - K Miura
- Shiga University of Medical Science, Department of Public Health, Shiga, Japan
| | - H Ueshima
- Shiga University of Medical Science, Department of Public Health, Shiga, Japan
| | - T Okamura
- Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
13
|
Mitsui K, Endo M, Imai Y, Ueda Y, Ogawa H, Muto G, Yan Y, Deshpande GA, Terao Y, Takeda S, Tanigawa T, Nishimura K, Hayashi K, Saito M, Kokaze A. Predictors of resignation and sick leave after cancer diagnosis among Japanese breast cancer survivors: a cross-sectional study. BMC Public Health 2021; 21:138. [PMID: 33446165 PMCID: PMC7809813 DOI: 10.1186/s12889-021-10168-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2020] [Accepted: 01/05/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND In Japan, 55.5% of breast cancer survivors (BCSs) are of working age, so various perspectives regarding return to work (RTW) after cancer diagnosis need to be considered. Therefore, this study aimed to clarify the risk factors for resignation and taking sick leave (SL) among BCSs in continued employment at the time of diagnosis. METHODS A web-based retrospective cross-sectional survey was conducted on BCSs using data from a 2018 Japanese national research project (Endo-Han) commissioned by the Ministry of Health, Labour and Welfare of Japan. The subjects were women aged 18-69 years who had been diagnosed with breast cancer for the first time at least 1 year previously. The risk factors for resignation and taking SL after breast cancer diagnosis, including age at diagnosis, education level, cancer stage, surgery, chemotherapy, radiotherapy, employment status, and occupational type, were then analyzed using a logistic regression model. RESULTS In total, 40 (14.9%) of 269 BCSs quit their jobs at least 1 year after being diagnosed with breast cancer. The results of the multivariable analysis indicated that lower education level (odds ratio [OR]: 3.802; 95% confidence interval [CI]: 1.233-11.729), taking SL (OR: 2.514; 95%CI: 1.202-5.261), and younger age at diagnosis (OR: 0.470; 95%CI: 0.221-0.998) were predictors of resignation. Of 229 patients who continued working, SL was taken by 72 (31.4%). In addition, undergoing surgery was found to be a predictor of taking SL (OR: 8.311; 95%CI: 1.007-68.621). CONCLUSIONS In total, 40 (14.9%) of 269 BCSs quit their jobs at least 1 year after being diagnosed with breast cancer. The results of this study indicated that younger age, lower education level, and taking SL were predictors of resignation after breast cancer diagnosis.
Collapse
Affiliation(s)
- Kiyomi Mitsui
- Department of Hygiene, Public Health, and Preventive Medicine, Showa University, Tokyo, Japan
| | - Motoki Endo
- Department of Public Health, Juntendo University Faculty of Medicine, Tokyo, Japan.
| | - Yuya Imai
- Department of Public Health, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Yuito Ueda
- Department of Public Health, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Hiroko Ogawa
- Department of Public Health, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Go Muto
- Department of Hygiene, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
| | - Yan Yan
- Department of Palliative Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | | | - Yasuhisa Terao
- Department of Obstetrics and Gynecology, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Satoru Takeda
- Department of Obstetrics and Gynecology, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Takeshi Tanigawa
- Department of Public Health, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Katsuji Nishimura
- Department of Psychiatry, Tokyo Women's Medical University School of Medicine, Tokyo, Japan
| | - Kazuhiko Hayashi
- Department of Chemotherapy and Palliative Care, Tokyo Women's Medical University Hospital, Tokyo, Japan
| | - Mitsue Saito
- Department of Breast Oncology, Juntendo University School of Medicine, Tokyo, Japan
| | - Akatsuki Kokaze
- Department of Hygiene, Public Health, and Preventive Medicine, Showa University, Tokyo, Japan
| |
Collapse
|
14
|
Ikemoto Y, Kuroda K, Endo M, Tanaka A, Sugiyama R, Nakagawa K, Sato Y, Kuribayashi Y, Tomooka K, Imai Y, Deshpande GA, Tanigawa T, Itakura A, Takeda S. Analysis of severe psychological stressors in women during fertility treatment: Japan-Female Employment and Mental health in Assisted reproductive technology (J-FEMA) study. Arch Gynecol Obstet 2021; 304:253-261. [PMID: 33386414 PMCID: PMC7775729 DOI: 10.1007/s00404-020-05923-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Accepted: 11/24/2020] [Indexed: 11/01/2022]
Abstract
PURPOSE To identify risk factors for severe psychological stress in women undergoing fertility treatment. METHODS This cross-sectional, multi-center study was conducted from August to December 2018. We recruited 1672 subjects who completed an anonymous, self-reported questionnaire regarding fertility treatment, conditions at work and home, and psychological stress using K6 score, which estimates psychological distress during the previous 30 days. We further focused our analysis on 1335 subjects who were working when starting fertility treatment. RESULTS Of 1672 women, mean K6 score (range 0-24) was 4.8 ± 4.4, including 103 women (6.2%) with K6 score ≥ 13 (high K6), and classified as probable severe psychological distress. Multivariate logistic regression analysis showed that high K6 was strongly associated with low annual family income of ≤ USD55,700 (JPY6 million) (odds ratio [OR] 1.89, 95% confidence interval [CI] 1.04-3.42), infertility duration of ≥ 2 years (OR 1.87, 95% CI 1.08-3.25), and no experience of childbirth (OR 2.04, 95% CI 1.05-3.97). Focusing on 1335 working women, 266 (19.9%) experienced resignation from work. High K6 was strongly associated with low family income (OR 2.83, 95% CI 1.52-5.28), cessation of professional duties (OR 2.08, 95% CI 1.05-4.14), infertility-related harassment in the workplace (OR 2.07, 95% CI 1.08-3.98), and perceived difficulties to continue working during fertility treatment (OR 2.94, 95% CI 1.15-7.50). CONCLUSION Severe psychological stressors in women during fertility treatment included low family income, long infertility duration, childlessness, infertility-related harassment, and perceived difficulty in working conditions or cessation from work. Establishment of mental health care support systems is urgently required in this population.
Collapse
Affiliation(s)
- Yuko Ikemoto
- Department of Obstetrics and Gynecology, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Keiji Kuroda
- Department of Obstetrics and Gynecology, Juntendo University Faculty of Medicine, Tokyo, Japan. .,Sugiyama Clinic Shinjuku, Center for Reproductive Medicine and Implantation Research, 1-19-6, Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
| | - Motoki Endo
- Department of Public Health, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Atsushi Tanaka
- Saint Mother Obstetrics and Gynecology Clinic, Institute for ART, Fukuoka, Japan
| | - Rikikazu Sugiyama
- Sugiyama Clinic Shinjuku, Center for Reproductive Medicine and Implantation Research, 1-19-6, Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan
| | - Koji Nakagawa
- Sugiyama Clinic Shinjuku, Center for Reproductive Medicine and Implantation Research, 1-19-6, Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan
| | - Yuichi Sato
- Tatedebari Sato Hospital, Obstetrics and Gynecology, Gunma, Japan.,Takasaki ART Clinic, Gunma, Japan
| | - Yasushi Kuribayashi
- Sugiyama Clinic Marunouchi, Center for Reproductive Medicine and Endoscopy, Tokyo, Japan
| | - Kiyohide Tomooka
- Department of Public Health, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Yuya Imai
- Department of Public Health, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Gautam A Deshpande
- Department of General Internal Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Takeshi Tanigawa
- Department of Public Health, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Atsuo Itakura
- Department of Obstetrics and Gynecology, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Satoru Takeda
- Department of Obstetrics and Gynecology, Juntendo University Faculty of Medicine, Tokyo, Japan
| |
Collapse
|
15
|
Imai Y, Endo M, Kuroda K, Tomooka K, Ikemoto Y, Sato S, Mitsui K, Ueda Y, Deshpande GA, Tanaka A, Sugiyama R, Nakagawa K, Sato Y, Kuribayashi Y, Itakura A, Takeda S, Tanigawa T. Risk factors for resignation from work after starting infertility treatment among Japanese women: Japan-Female Employment and Mental health in Assisted reproductive technology (J-FEMA) study. Occup Environ Med 2020; 78:oemed-2020-106745. [PMID: 33273052 PMCID: PMC8142458 DOI: 10.1136/oemed-2020-106745] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2020] [Revised: 10/28/2020] [Accepted: 11/09/2020] [Indexed: 11/23/2022]
Abstract
OBJECTIVE To elucidate the risk factors associated with resignation from work of Japanese women undergoing infertility treatment. METHODS A total of 1727 female patients who attended a private fertility clinic in Japan participated in the Japan-Female Employment and Mental health in Assisted reproductive technology study. Questions related to demographic, clinical and socioeconomic characteristics were employed in the questionnaire. Out of the 1727 patients, 1075 patients who were working at the time of initiating infertility treatment and felt infertility treatment incompatible with work were included in the analysis. Risk factors for resignation were assessed by using multivariable logistic regression models. RESULTS Among 1075 working women who started infertility treatment, 179 (16.7%) subsequently resigned. Multivariable-adjusted ORs for resignation in those with lower educational background and infertility for ≥2 years were 1.58 (95% CI: 1.07 to 2.34) and 1.82 (95% CI: 1.15 to 2.89), respectively. The OR for resignation in non-permanent workers undergoing infertility treatment was 2.65 (95% CI: 1.61 to 4.37). While experiencing harassment in the workplace approached significance, lack of support from the company was significantly associated with resignation after starting infertility treatment, with ORs of 1.71 (95% CI: 0.98 to 2.99) and 1.91 (95% CI: 1.28 to 2.86), respectively. CONCLUSION One-sixth of women resigned after starting infertility treatments. It was found that factors related to education, infertility duration and work environment were significantly associated with resignation. Reducing the physical and psychological burden endured by women, for example, by increasing employer-provided support, is vitally important in balancing infertility treatment with maintenance of work life.
Collapse
Affiliation(s)
- Yuya Imai
- Department of Public Health, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
| | - Motoki Endo
- Department of Public Health, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
| | - Keiji Kuroda
- Department of Obstetrics and Gynecology, Juntendo University Faculty of Medicine, Bunkyo-ku, Tokyo, Japan
- Center for Reproductive Medicine and Implantation Research, Sugiyama Clinic Shinjuku, Shinjuku-ku, Tokyo, Japan
| | - Kiyohide Tomooka
- Department of Public Health, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
| | - Yuko Ikemoto
- Department of Obstetrics and Gynecology, Juntendo University Faculty of Medicine, Bunkyo-ku, Tokyo, Japan
| | - Setsuko Sato
- Department of Public Health, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
| | - Kiyomi Mitsui
- Department of Hygiene, Public Health, and Preventive Medicine, Showa University, Shinagawa-ku, Tokyo, Japan
| | - Yuito Ueda
- Department of Public Health, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
| | - Gautam A Deshpande
- Department of General Internal Medicine, Juntendo University Faculty of Medicine, Bunkyo-ku, Tokyo, Japan
| | - Atsushi Tanaka
- Saint Mother Hospital Infertility Clinic, Kitakyushu, Fukuoka, Japan
| | - Rikikazu Sugiyama
- Center for Reproductive Medicine and Implantation Research, Sugiyama Clinic Shinjuku, Shinjuku-ku, Tokyo, Japan
| | - Koji Nakagawa
- Center for Reproductive Medicine and Implantation Research, Sugiyama Clinic Shinjuku, Shinjuku-ku, Tokyo, Japan
| | | | - Yasushi Kuribayashi
- Center for Reproductive Medicine and Endoscopy Sugiyama Clinic Marunouchi, Chiyoda-ku, Tokyo, Japan
| | - Atsuo Itakura
- Department of Obstetrics and Gynecology, Juntendo University Faculty of Medicine, Bunkyo-ku, Tokyo, Japan
| | - Satoru Takeda
- Department of Obstetrics and Gynecology, Juntendo University Faculty of Medicine, Bunkyo-ku, Tokyo, Japan
| | - Takeshi Tanigawa
- Department of Public Health, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
| |
Collapse
|
16
|
Imai Y, Nagai N, Yasuda K, Kusakabe M, Inoue Y, Natsuaki M, Yamanishi K. 316 Dupilumab effects on the circulating ILC2 population and ILC2/3 repertoire in patients with atopic dermatitis. J Invest Dermatol 2020. [DOI: 10.1016/j.jid.2020.03.323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
17
|
Kinoshita M, Kaneko Y, Watanabe M, Imai Y, Shrestha S, Suwa J, Ohishi Y, Hamatani H, Nakasatomi M, Sakairi T, Ikeuchi H, Nojima Y, Hiromura K. OP0306 CD11C-SPECIFIC ABLATION OF SHP1 INDUCES AUTOIMMUNE SIALADENITIS SIMILAR TO SJÖGREN’S SYNDROME. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Dendritic cells (DCs) play important roles in inducing immune response as well as maintaining immune tolerance. Src homology 2 domain-containing protein tyrosine phosphatase-1 (Shp1) is a negative regulator of signaling in hematopoietic cells and is expressed in a variety of immune cells including DCs. Shp1 homozygous mutant mice (motheaten mice) develop multiple immunological abnormalities and they die around four weeks after birth because of severe pneumonitis. Motheaten mice produce large amounts of autoantibodies, and besides, B-1a cells, a distinct B cell subset, which are an important source of autoantibodies increase in these mice. The functional abnormality of DCs in motheaten mice has not been characterized, but DCs and macrophages increase in various organs of motheaten mice.To analyze the function of Shp1 in DCs, we generated Shp1 conditional knockout mice (Shp1 CKO) in whichShp1gene is specifically depleted in CD11c+cells. We found that aged shp1 CKO developed autoimmune glomerulonephritis. We also found that they developed severe tubulointerstitial nephritis (TIN) at the age of 40 weeks, which is characterized by the infiltration of CD11c+and F4/80+cells. CD4+T cells from Shp1 CKO produce much more amount of IFNγ. Collectively, Shp1 in DCs acts as a key regulatory molecule to protect against autoimmunity.Objectives:We analyzed salivary glands of CKO to confirm whether they have autoimmune sialadenitis because TIN is known to be the most common renal manifestations of Sjögren’s syndrome in human.Methods:Shp1 CKO are generated by crossing a mouse line carrying floxedShp1allele to mice expressing Cre recombinase under the control of the CD11c promoter. Sex- and age-matchedPtpn6fl/fllittermates withoutCregene were studied as controls. We analyzed secretory function of the salivary glands in response to pilocarpine stimulation in Shp1 CKO at the age of 40 weeks or older. We then performed histological examination of salivary glands (submandibular glands and sublingual glands) with light-microscopy and immunohistochemical staining. The mononuclear cells prepared from the salivary glands were analyzed by flow cytometry (FCM). We also quantified anti-SSA/Ro60 antibodies and anti-SSB/LA antibodies by ELISA.Results:Shp1 CKO secreted less saliva flow compared to control mice by pilocarpine stimulation. Histological study showed Shp1 CKO exhibited massive infiltration of inflammatory cells in salivary glands associated with periductal foci and periductal fibrosis. Most of infiltrated cells were stained by anti- CD4 or B220 mAbs. FCM revealed that B cells increased in the salivary glands of Shp1 CKO. In addition, B-1a cells also increased in the salivary glands of the mice. The levels of anti-SSA/Ro60 antibodies and anti-SSB/LA antibodies were increased in Shp1 CKO.Conclusion:CD11c-specific ablation of Shp1 induces the ectopic generation of lymphoid structure in salivary glands and impairment of salivary secretion. Autoantibody profile in Shp1 CKO resembled that in human Sjögren’s syndrome. Our findings suggest that aged Shp1 CKO have the potential to become a new mouse model for the analysis of Sjögren’s syndrome.References:[1]Green C. M. et al. J Heredity. 1975; 250-258.[2]Kaneko T. et al. J Immunology. 2012; 5397-540.[3]Watanabe M. et al. Biochem Biophys Rep. in press.Disclosure of Interests:Masato Kinoshita: None declared, Yoriaki Kaneko Grant/research support from: CHUGAI PHARMACEUTICAL CO., LTD.Astellas Pharma Inc.b, Speakers bureau: CHUGAI PHARMACEUTICAL CO., LTD.Astellas Pharma Inc., Mitsuharu Watanabe: None declared, Yoichi Imai: None declared, Shreya Shrestha: None declared, Junya Suwa: None declared, Yuko Ohishi: None declared, Hiroko Hamatani: None declared, Masao Nakasatomi: None declared, Toru Sakairi: None declared, Hidekazu Ikeuchi Speakers bureau: CHUGAI PHARMACEUTICAL CO., LTD.Astellas Pharma Inc., Yoshihisa Nojima: None declared, Keiju Hiromura Grant/research support from: CHUGAI PHARMACEUTICAL CO., LTD.Astellas Pharma Inc., Speakers bureau: CHUGAI PHARMACEUTICAL CO., LTD.Astellas Pharma Inc.
Collapse
|
18
|
Imai Y, Ikeuchi H, Suwa J, Ohishi Y, Watanabe M, Nakasatomi M, Hamatani H, Sakairi T, Kaneko Y, Hiromura K. SAT0177 MULTITARGET THERAPY WITH TACROLIMUS AND MYCOPHENOLATE MOFETIL FOR TREATMENT OF LUPUS NEPHRITIS PRESENTED WITH RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1775] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Although, most lupus nephritis patients present with chronic glomerulonephritis or nephrotic syndrome, some patients develop rapidly progressive glomerulonephritis (RPGN), which is a clinical syndrome characterized by rapid loss of renal function over a short period of time (days to months). Multitarget therapy using tacrolimus and mycophenolate mofetil (MMF) has been reported to be effective as induction therapy of Class III to Class V lupus nephritis1. However, its efficacy on lupus nephritis presented with RPGN has not been well reported.Objectives:We aimed to examine the efficacy of multitarget therapy on lupus nephritis presented with RPGN.Methods:We retrospectively analyzed patients with biopsy-proven lupus nephritis, who clinically showed RPGN, and were treated by multitarget therapy with tacrolimus and MMF in our department. Data were expressed as mean±SD.Results:Five lupus nephritis patients (3 female) with RPGN were treated by multitarget therapy as induction therapy. Mean age was 36.6±13.5 years old. Renal biopsy at treatment revealed Class IV(A) in 2, Class IV(A+C) in 1 and Class IV(A)+V in 2. The percentage of glomerular crescents was 23.1±25.4%. eGFR and proteinuria at the initiation of treatment were 46.8±11.5 mL/min/1.73m2and 7.7±3.4 g/gCr, respectively. Patients were initially treated with methylprednisolone pulse therapy followed by 0.8-1.0 mg/kg of prednisolone (PSL), 2-3 mg/day of tacrolimus and 1000 mg/day of MMF. At 6 months, eGFR and proteinuria improved to 72.9±11.3 mL/min/1.73m2and 0.19±0.13 g/gCr, respectively. At 12 months, eGFR and proteinuria further improved to 76.8±7.8 mL/min/1.73m2and 0.10±0.07 g/gCr, respectively and the dose of PSL was reduced to 6.6±1.5 mg/day. Three patients became positive for cytomegalovirus antigenemia and were successfully treated with antiviral therapy.Conclusion:Multitarget therapy is effective in lupus nephritis even in patients presented with RPGN.References:[1]Liu Z, Zhang H, Liu Z,et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial.Ann Int Med2015; 162: 18-26.Disclosure of Interests:Yoichi Imai: None declared, Hidekazu Ikeuchi Speakers bureau: CHUGAI PHARMACEUTICAL CO., LTD.Astellas Pharma Inc., Junya Suwa: None declared, Yuko Ohishi: None declared, Mitsuharu Watanabe: None declared, Masao Nakasatomi: None declared, Hiroko Hamatani: None declared, Toru Sakairi: None declared, Yoriaki Kaneko Grant/research support from: CHUGAI PHARMACEUTICAL CO., LTD.Astellas Pharma Inc. b, Speakers bureau: CHUGAI PHARMACEUTICAL CO., LTD.Astellas Pharma Inc., Keiju Hiromura Grant/research support from: CHUGAI PHARMACEUTICAL CO., LTD.Astellas Pharma Inc., Speakers bureau: CHUGAI PHARMACEUTICAL CO., LTD.Astellas Pharma Inc.
Collapse
|
19
|
Gou B, Arvieux J, Aulenbacher K, Ríos DB, Baunack S, Becker D, Capozza L, Deconinck W, Diefenbach J, Frascaria R, Gorchtein M, Gläser B, von Harrach D, Imai Y, Kabuß EM, Kothe R, Kowalski S, Kunne R, Maas FE, Merkel H, Espí MCM, Morlet M, Müller U, Ong S, Schilling E, Weinrich C, van de Wiele J, Zambrana M, Zimmermann I. Study of Two-Photon Exchange via the Beam Transverse Single Spin Asymmetry in Electron-Proton Elastic Scattering at Forward Angles over a Wide Energy Range. Phys Rev Lett 2020; 124:122003. [PMID: 32281834 DOI: 10.1103/physrevlett.124.122003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/14/2020] [Revised: 02/28/2020] [Accepted: 02/28/2020] [Indexed: 06/11/2023]
Abstract
We report on a new measurement of the beam transverse single spin asymmetry in electron-proton elastic scattering, A_{⊥}^{ep}, at five beam energies from 315.1 to 1508.4 MeV and at a scattering angle of 30°<θ<40°. The covered Q^{2} values are 0.032, 0.057, 0.082, 0.218, 0.613 (GeV/c)^{2}. The measurement clearly indicates significant inelastic contributions to the two-photon-exchange (TPE) amplitude in the low-Q^{2} kinematic region. No theoretical calculation is able to reproduce our result. Comparison with a calculation based on unitarity, which only takes into account elastic and πN inelastic intermediate states, suggests that there are other inelastic intermediate states such as ππN, KΛ, and ηN. Covering a wide energy range, our new high-precision data provide a benchmark to study those intermediate states.
Collapse
Affiliation(s)
- B Gou
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
- Helmholtz-Institut Mainz, Johannes Gutenberg-Universität Mainz, Staudingerweg 18, D-55099 Mainz, Germany
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, China
| | - J Arvieux
- Institut de Physique Nucléaire, CNRS-IN2P3, Université Paris-Sud, F-91406 Orsay Cedex, France
| | - K Aulenbacher
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
- Helmholtz-Institut Mainz, Johannes Gutenberg-Universität Mainz, Staudingerweg 18, D-55099 Mainz, Germany
| | - D Balaguer Ríos
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - S Baunack
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - D Becker
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - L Capozza
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
- Helmholtz-Institut Mainz, Johannes Gutenberg-Universität Mainz, Staudingerweg 18, D-55099 Mainz, Germany
| | - W Deconinck
- Laboratory for Nuclear Science and Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - J Diefenbach
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - R Frascaria
- Institut de Physique Nucléaire, CNRS-IN2P3, Université Paris-Sud, F-91406 Orsay Cedex, France
| | - M Gorchtein
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - B Gläser
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - D von Harrach
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - Y Imai
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - E-M Kabuß
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - R Kothe
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - S Kowalski
- Laboratory for Nuclear Science and Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - R Kunne
- Institut de Physique Nucléaire, CNRS-IN2P3, Université Paris-Sud, F-91406 Orsay Cedex, France
| | - F E Maas
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
- Helmholtz-Institut Mainz, Johannes Gutenberg-Universität Mainz, Staudingerweg 18, D-55099 Mainz, Germany
| | - H Merkel
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - M C Mora Espí
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - M Morlet
- Institut de Physique Nucléaire, CNRS-IN2P3, Université Paris-Sud, F-91406 Orsay Cedex, France
| | - U Müller
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - S Ong
- Institut de Physique Nucléaire, CNRS-IN2P3, Université Paris-Sud, F-91406 Orsay Cedex, France
| | - E Schilling
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - C Weinrich
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - J van de Wiele
- Institut de Physique Nucléaire, CNRS-IN2P3, Université Paris-Sud, F-91406 Orsay Cedex, France
| | - M Zambrana
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
- Helmholtz-Institut Mainz, Johannes Gutenberg-Universität Mainz, Staudingerweg 18, D-55099 Mainz, Germany
| | - I Zimmermann
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
- Helmholtz-Institut Mainz, Johannes Gutenberg-Universität Mainz, Staudingerweg 18, D-55099 Mainz, Germany
| |
Collapse
|
20
|
Endo M, Haruyama Y, Muto G, Imai Y, Mitsui K, Mizoue T, Wada H, Kobashi G, Tanigawa T. Recurrent sick leave and resignation rates among female cancer survivors after return to work: the Japan sickness absence and return to work (J-SAR) study. BMC Public Health 2019; 19:1248. [PMID: 31510964 PMCID: PMC6737646 DOI: 10.1186/s12889-019-7509-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2019] [Accepted: 08/16/2019] [Indexed: 11/10/2022] Open
Abstract
Background To date, there have not been any workforce-based Japanese cohort studies investigating work sustainability after return to work (RTW). The objective of this study was to investigate the post-RTW cumulative recurrent sick leave rate and cumulative resignation rate among female cancer survivors. Methods Among Japanese employees who were registered in the Japan sickness absence and return to work (J-SAR) study, the subjects were those female employees who returned to work after sick leave due to newly clinically diagnosed cancer (C01-C99; ICD-10), based on a physician’s certificate, between 2000 and 2011. The last day of the follow-up period was December 31, 2012. The recurrent sickness leave rate and resignation rate were calculated using competing risk survival analysis. Results Of 223 cancer survivors, 61 took further physician-certified sick leave after their RTW. The median duration of the post-RTW work period among all cancer survivors was 10.6 years. The work continuance rates of the female cancer survivors were 83.2 and 60.4% at 1 and 5 years after they returned to work, respectively. There was a steep reduction in the work continuance rate during the first post-RTW year. There were considerable differences in the work continuance rate according to the primary cancer site. Cumulative recurrent sick leave rates of 11.8 and 28.9% were seen at 1 and 5 years after the subjects returned to work. The cumulative resignation rate was 5.0 and 10.7% at 1 and 5 years after the subjects returned to work. Most recurrent sick leave occurred in the first year after the subjects returned to work, followed by the second year. Conclusions Sixty percent of female cancer survivors were still working at 5 years after returning to work, although the work continuance rates for different types of cancer varied significantly.
Collapse
Affiliation(s)
- Motoki Endo
- Department of Public Health, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
| | - Yasuo Haruyama
- Department of Public Health, Dokkyo University School of Medicine, Tochigi, Japan
| | - Go Muto
- Department of Epidemiology and Environmental Health, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Yuya Imai
- Department of Public Health, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan
| | - Kiyomi Mitsui
- Department of Hygiene, Public Health and Preventive Medicine, Showa University, Tokyo, Japan
| | - Tetsuya Mizoue
- Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
| | - Hiroo Wada
- Department of Public Health, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan
| | - Gen Kobashi
- Department of Public Health, Dokkyo University School of Medicine, Tochigi, Japan
| | - Takeshi Tanigawa
- Department of Public Health, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan
| |
Collapse
|
21
|
NAKAYAMA S, Satoh M, Metoki H, Murakami T, Kikuya M, Mori T, Hozawa A, Node K, Imai Y, Ohkubo T. SUN-224 N-TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE IS A PREDICTOR OF CHRONIC KIDNEY DISEASE INCIDENCE IN AN ASIAN GENERAL POPULATION:THE OHASAMA STUDY. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
22
|
Imai Y, Yamamoto T, Sekimoto A, Okano Y, Sato R, Shigeta Y. Numerical investigation of the nano-scale solutal Marangoni convections. J Taiwan Inst Chem Eng 2019. [DOI: 10.1016/j.jtice.2018.05.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
23
|
Tanaka T, Suga T, Imai Y, Ueno H, Misaki J, Miyake Y, Otsuka M, Nagano A, Isaka T. Characteristics of lower leg and foot muscle thicknesses in sprinters: Does greater foot muscles contribute to sprint performance? Eur J Sport Sci 2018; 19:442-450. [PMID: 30360695 DOI: 10.1080/17461391.2018.1534991] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
The present study aimed to determine the differences in thicknesses of the lower leg and foot muscles between sprinters and non-sprinters and to examine the relationship between these muscle thicknesses and sprint performance in sprinters. Twenty-six well-trained sprinters and 26 body size-matched non-sprinters participated in this study. Total 9 muscle thicknesses of bilateral lower leg and foot muscles in participants were measured using ultrasonography. Regarding the lower leg muscles, thicknesses of the tibialis anterior, gastrocnemius medial, and gastrocnemius lateral were measured. Regarding the foot muscles, thicknesses of the flexor digitorum longus, flexor hallucis longus, peroneal longus and brevis, abductor hallucis, flexor digitorum brevis, and flexor hallucis brevis were measured. Most muscle thicknesses were significantly larger in sprinters than in non-sprinters. The differences in mean thicknesses of both legs between the two groups were greater in the foot muscles, where it ranged from 10.2% to 17.1%, than in the lower leg muscles, where it ranged from -0.9% to 9.4%. Among foot muscles, the thickness of only the abductor hallucis was positively correlated with the personal best 100-m sprint time in sprinters (r = 0.419, P = 0.033), indicating that a greater abductor hallucis may be a negative factor for superior sprint performance. These findings suggest that although the foot muscles in addition to the lower leg muscles are more developed in sprinters than in non-sprinters, these muscle sizes may not contribute to achieve superior sprint performance.
Collapse
Affiliation(s)
- Takahiro Tanaka
- a Faculty of Sport and Health Science , Ritsumeikan University , Kusatsu , Japan
| | - Tadashi Suga
- a Faculty of Sport and Health Science , Ritsumeikan University , Kusatsu , Japan
| | - Yuya Imai
- a Faculty of Sport and Health Science , Ritsumeikan University , Kusatsu , Japan
| | - Hiromasa Ueno
- a Faculty of Sport and Health Science , Ritsumeikan University , Kusatsu , Japan
| | - Jun Misaki
- a Faculty of Sport and Health Science , Ritsumeikan University , Kusatsu , Japan
| | - Yuto Miyake
- a Faculty of Sport and Health Science , Ritsumeikan University , Kusatsu , Japan
| | - Mitsuo Otsuka
- a Faculty of Sport and Health Science , Ritsumeikan University , Kusatsu , Japan
| | - Akinori Nagano
- a Faculty of Sport and Health Science , Ritsumeikan University , Kusatsu , Japan
| | - Tadao Isaka
- a Faculty of Sport and Health Science , Ritsumeikan University , Kusatsu , Japan
| |
Collapse
|
24
|
Dobrian AD, Morris MA, Taylor-Fishwick DA, Holman TR, Imai Y, Mirmira RG, Nadler JL. Role of the 12-lipoxygenase pathway in diabetes pathogenesis and complications. Pharmacol Ther 2018; 195:100-110. [PMID: 30347209 DOI: 10.1016/j.pharmthera.2018.10.010] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
12-lipoxygenase (12-LOX) is one of several enzyme isoforms responsible for the metabolism of arachidonic acid and other poly-unsaturated fatty acids to both pro- and anti-inflammatory lipid mediators. Mounting evidence has shown that 12-LOX plays a critical role in the modulation of inflammation at multiple checkpoints during diabetes development. Due to this, interventions to limit pro-inflammatory 12-LOX metabolites either by isoform-specific 12-LOX inhibition, or by providing specific fatty acid substrates via dietary intervention, has the potential to significantly and positively impact health outcomes of patients living with both type 1 and type 2 diabetes. To date, the development of truly specific and efficacious inhibitors has been hampered by homology of LOX family members; however, improvements in high throughput screening have improved the inhibitor landscape. Here, we describe the function and role of human 12-LOX, and mouse 12-LOX and 12/15-LOX, in the development of diabetes and diabetes-related complications, and describe promise in the development of strategies to limit pro-inflammatory metabolites, primarily via new small molecule 12-LOX inhibitors.
Collapse
Affiliation(s)
- A D Dobrian
- Department of Physiological Sciences, Eastern Virginia Medical School, Norfolk, VA, United States
| | - M A Morris
- Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, VA, United States
| | - D A Taylor-Fishwick
- Department of Microbiology, Cell and Molecular Biology, Eastern Virginia Medical School, Norfolk, VA, United States
| | - T R Holman
- Department of Chemistry and Biochemistry, University of California Santa Cruz, Santa Cruz, CA, United States
| | - Y Imai
- University of Iowa Carver College of Medicine, Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa, city, IA, United States
| | - R G Mirmira
- Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA; Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA; Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA; Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, Indiana, USA
| | - J L Nadler
- Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, VA, United States.
| |
Collapse
|
25
|
Tanaka R, Lee SW, Kawai M, Tashiro K, Imai Y, Uchiyama K. Incidence and risk factors of postoperative delirium in elderly patients who underwent gastrectomy for gastric cancer. Clin Nutr 2018. [DOI: 10.1016/j.clnu.2018.06.2086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
26
|
Gnatiuc L, Herrington WG, Halsey J, Tuomilehto J, Fang X, Kim HC, De Bacquer D, Dobson AJ, Criqui MH, Jacobs DR, Leon DA, Peters SAE, Ueshima H, Sherliker P, Peto R, Collins R, Huxley RR, Emberson JR, Woodward M, Lewington S, Aoki N, Arima H, Arnesen E, Aromaa A, Assmann G, Bachman DL, Baigent C, Bartholomew H, Benetos A, Bengtsson C, Bennett D, Björkelund C, Blackburn H, Bonaa K, Boyle E, Broadhurst R, Carstensen J, Chambless L, Chen Z, Chew SK, Clarke R, Cox C, Curb JD, D'Agostino R, Date C, Davey Smith G, De Backer G, Dhaliwal SS, Duan XF, Ducimetiere P, Duffy S, Eliassen H, Elwood P, Empana J, Garcia-Palmieri MH, Gazes P, Giles GG, Gillis C, Goldbourt U, Gu DF, Guasch-Ferre M, Guize L, Haheim L, Hart C, Hashimoto S, Hashimoto T, Heng D, Hjermann I, Ho SC, Hobbs M, Hole D, Holme I, Horibe H, Hozawa A, Hu F, Hughes K, Iida M, Imai K, Imai Y, Iso H, Jackson R, Jamrozik K, Jee SH, Jensen G, Jiang CQ, Johansen NB, Jorgensen T, Jousilahti P, Kagaya M, Keil J, Keller J, Kim IS, Kita Y, Kitamura A, Kiyohara Y, Knekt P, Knuiman M, Kornitzer M, Kromhout D, Kronmal R, Lam TH, Law M, Lee J, Leren P, Levy D, Li YH, Lissner L, Luepker R, Luszcz M, MacMahon S, Maegawa H, Marmot M, Matsutani Y, Meade T, Morris J, Morris R, Murayama T, Naito Y, Nakachi K, Nakamura M, Nakayama T, Neaton J, Nietert PJ, Nishimoto Y, Norton R, Nozaki A, Ohkubo T, Okayama A, Pan WH, Puska P, Qizilbash N, Reunanen A, Rimm E, Rodgers A, Saitoh S, Sakata K, Sato S, Schnohr P, Schulte H, Selmer R, Sharp D, Shifu X, Shimamoto K, Shipley M, Silbershatz H, Sorlie P, Sritara P, Suh I, Sutherland SE, Sweetnam P, Tamakoshi A, Tanaka H, Thomsen T, Tominaga S, Tomita M, Törnberg S, Tunstall-Pedoe H, Tverdal A, Ueshima H, Vartiainen E, Wald N, Wannamethee SG, Welborn TA, Whincup P, Whitlock G, Willett W, Woo J, Wu ZL, Yao SX, Yarnell J, Yokoyama T, Yoshiike N, Zhang XH. Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies. Lancet Diabetes Endocrinol 2018; 6:538-546. [PMID: 29752194 PMCID: PMC6008496 DOI: 10.1016/s2213-8587(18)30079-2] [Citation(s) in RCA: 129] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/15/2017] [Revised: 02/20/2018] [Accepted: 02/26/2018] [Indexed: 01/06/2023]
Abstract
BACKGROUND Several studies have shown that diabetes confers a higher relative risk of vascular mortality among women than among men, but whether this increased relative risk in women exists across age groups and within defined levels of other risk factors is uncertain. We aimed to determine whether differences in established risk factors, such as blood pressure, BMI, smoking, and cholesterol, explain the higher relative risks of vascular mortality among women than among men. METHODS In our meta-analysis, we obtained individual participant-level data from studies included in the Prospective Studies Collaboration and the Asia Pacific Cohort Studies Collaboration that had obtained baseline information on age, sex, diabetes, total cholesterol, blood pressure, tobacco use, height, and weight. Data on causes of death were obtained from medical death certificates. We used Cox regression models to assess the relevance of diabetes (any type) to occlusive vascular mortality (ischaemic heart disease, ischaemic stroke, or other atherosclerotic deaths) by age, sex, and other major vascular risk factors, and to assess whether the associations of blood pressure, total cholesterol, and body-mass index (BMI) to occlusive vascular mortality are modified by diabetes. RESULTS Individual participant-level data were analysed from 980 793 adults. During 9·8 million person-years of follow-up, among participants aged between 35 and 89 years, 19 686 (25·6%) of 76 965 deaths were attributed to occlusive vascular disease. After controlling for major vascular risk factors, diabetes roughly doubled occlusive vascular mortality risk among men (death rate ratio [RR] 2·10, 95% CI 1·97-2·24) and tripled risk among women (3·00, 2·71-3·33; χ2 test for heterogeneity p<0·0001). For both sexes combined, the occlusive vascular death RRs were higher in younger individuals (aged 35-59 years: 2·60, 2·30-2·94) than in older individuals (aged 70-89 years: 2·01, 1·85-2·19; p=0·0001 for trend across age groups), and, across age groups, the death RRs were higher among women than among men. Therefore, women aged 35-59 years had the highest death RR across all age and sex groups (5·55, 4·15-7·44). However, since underlying confounder-adjusted occlusive vascular mortality rates at any age were higher in men than in women, the adjusted absolute excess occlusive vascular mortality associated with diabetes was similar for men and women. At ages 35-59 years, the excess absolute risk was 0·05% (95% CI 0·03-0·07) per year in women compared with 0·08% (0·05-0·10) per year in men; the corresponding excess at ages 70-89 years was 1·08% (0·84-1·32) per year in women and 0·91% (0·77-1·05) per year in men. Total cholesterol, blood pressure, and BMI each showed continuous log-linear associations with occlusive vascular mortality that were similar among individuals with and without diabetes across both sexes. INTERPRETATION Independent of other major vascular risk factors, diabetes substantially increased vascular risk in both men and women. Lifestyle changes to reduce smoking and obesity and use of cost-effective drugs that target major vascular risks (eg, statins and antihypertensive drugs) are important in both men and women with diabetes, but might not reduce the relative excess risk of occlusive vascular disease in women with diabetes, which remains unexplained. FUNDING UK Medical Research Council, British Heart Foundation, Cancer Research UK, European Union BIOMED programme, and National Institute on Aging (US National Institutes of Health).
Collapse
|
27
|
Imai Y, Nagai M, Kusakabe M, Yasuda K, Nakanishi K, Yoshimoto T, Yamanishi K. 902 Ablation of basophils reduces ILC2-dependent atopic dermatitis-like inflammation in mice overexpressing interleukin-33 in the skin. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.914] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
28
|
Imai Y, Nihei M, Abe K, Sasaki S, Minami N, Munakata M, Yumita S, Onoda Y, Sekino H, Yamakoshi K, Yoshinaga K. A Finger Volume-Oscillometric Device for Monitoring Ambulatory Blood Pressure: Laboratory and Clinical Evaluations. ACTA ACUST UNITED AC 2018. [DOI: 10.1080/07300077.1987.11978712] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
- Y. Imai
- Department of Medicine, Tohoku University, Sapporo, Japan
| | - M. Nihei
- Department of Medicine, Tohoku University, Sapporo, Japan
| | - K. Abe
- Department of Medicine, Tohoku University, Sapporo, Japan
| | - S. Sasaki
- Department of Medicine, Tohoku University, Sapporo, Japan
| | - N. Minami
- Department of Medicine, Tohoku University, Sapporo, Japan
| | - M. Munakata
- Department of Medicine, Tohoku University, Sapporo, Japan
| | - S. Yumita
- Department of Medicine, Tohoku University, Sapporo, Japan
| | - Y. Onoda
- Department of Medicine, Tohoku University, Sapporo, Japan
| | - H. Sekino
- Kohjinkai Central Hospital, Sendai, Sapporo, Japan
| | - K. Yamakoshi
- Research Institute of Applied Electricity, Hokkaido University, Sapporo, Japan
| | - K. Yoshinaga
- Department of Medicine, Tohoku University, Sapporo, Japan
| |
Collapse
|
29
|
Shimozawa M, Hashimoto K, Ueda A, Suzuki Y, Sugii K, Yamada S, Imai Y, Kobayashi R, Itoh K, Iguchi S, Naka M, Ishihara S, Mori H, Sasaki T, Yamashita M. Quantum-disordered state of magnetic and electric dipoles in an organic Mott system. Nat Commun 2017; 8:1821. [PMID: 29180819 PMCID: PMC5703743 DOI: 10.1038/s41467-017-01849-x] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Accepted: 10/18/2017] [Indexed: 11/24/2022] Open
Abstract
Strongly enhanced quantum fluctuations often lead to a rich variety of quantum-disordered states. Developing approaches to enhance quantum fluctuations may open paths to realize even more fascinating quantum states. Here, we demonstrate that a coupling of localized spins with the zero-point motion of hydrogen atoms, that is, proton fluctuations in a hydrogen-bonded organic Mott insulator provides a different class of quantum spin liquids (QSLs). We find that divergent dielectric behavior associated with the approach to hydrogen-bond order is suppressed by the quantum proton fluctuations, resulting in a quantum paraelectric (QPE) state. Furthermore, our thermal-transport measurements reveal that a QSL state with gapless spin excitations rapidly emerges upon entering the QPE state. These findings indicate that the quantum proton fluctuations give rise to a QSL—a quantum-disordered state of magnetic and electric dipoles—through the coupling between the electron and proton degrees of freedom. The organic material κ-H3(Cat-EDT-TTF)2 has been suggested to exhibit a quantum spin liquid phase in which quantum fluctuations prevent the formation of magnetic order. Here, the authors show that this may be a result of fluctuations of hydrogen atoms, rather than more conventional geometric frustration.
Collapse
Affiliation(s)
- M Shimozawa
- The Institute for Solid State Physics, The University of Tokyo, Kashiwa, Chiba, 277-8581, Japan.
| | - K Hashimoto
- Institute for Materials Research, Tohoku University, Aoba-ku, Sendai, 980-8577, Japan.
| | - A Ueda
- The Institute for Solid State Physics, The University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - Y Suzuki
- The Institute for Solid State Physics, The University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - K Sugii
- The Institute for Solid State Physics, The University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - S Yamada
- The Institute for Solid State Physics, The University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - Y Imai
- The Institute for Solid State Physics, The University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - R Kobayashi
- Institute for Materials Research, Tohoku University, Aoba-ku, Sendai, 980-8577, Japan
| | - K Itoh
- Institute for Materials Research, Tohoku University, Aoba-ku, Sendai, 980-8577, Japan
| | - S Iguchi
- Institute for Materials Research, Tohoku University, Aoba-ku, Sendai, 980-8577, Japan
| | - M Naka
- Department of Physics, Tohoku University, Sendai, 980-8578, Japan.,Waseda Institute for Advanced Study, Waseda University, Shinjuku, Tokyo, 169-8050, Japan
| | - S Ishihara
- Department of Physics, Tohoku University, Sendai, 980-8578, Japan
| | - H Mori
- The Institute for Solid State Physics, The University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - T Sasaki
- Institute for Materials Research, Tohoku University, Aoba-ku, Sendai, 980-8577, Japan
| | - M Yamashita
- The Institute for Solid State Physics, The University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| |
Collapse
|
30
|
Kamiya N, Imai Y, Asai-Sato M, Ota Y, Suzuki Y, Ruiz-Yokota N, Matsunaga T, Miyagi E. Efficacy and feasibility of paclitaxel and carboplatin-based concurrent chemoradiotherapy for patients with advanced cervical cancer with renal dysfunction. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx663.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Nosaki K, Takeuchi S, Takahara S, Kawakami T, Yoh K, Kono Y, Horiike A, Seto T, Goto K, Yoshimura K, Imai Y, Murayama T, Yano S. Safety of alectinib in non-small cell lung cancer patients with RET fusion gene (ALL-RET): Results from the dose-finding portion of a phase 1/2 study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx671.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
32
|
Hibi T, Imai Y, Murata Y, Matsushima N, Zheng R, Gasink C. Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies. Intest Res 2017; 15:475-486. [PMID: 29142515 PMCID: PMC5683978 DOI: 10.5217/ir.2017.15.4.475] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/31/2016] [Revised: 03/10/2017] [Accepted: 03/10/2017] [Indexed: 12/15/2022] Open
Abstract
Background/Aims Efficacy and safety of ustekinumab were evaluated in a Japanese subpopulation with moderately to severely active Crohn's disease (CD) in UNITI-1, UNITI-2 and IM-UNITI studies and results were compared with the overall population. Methods Overall, patients in UNITI-1 (Japan, n=56; failed response to tumor necrosis factor antagonist) and UNITI-2 (Japan, n=26; failed response to prior conventional therapy) were randomized to placebo or ustekinumab intravenous induction (130 mg or ~6 mg/kg) at week 0. Responders to ustekinumab induction therapy (Japan, n=21) were randomized to placebo or ustekinumab (90 mg, subcutaneous) maintenance (every 12 weeks [q12w] or 8 weeks [q8w]) in IM-UNITI. The primary endpoint was clinical response at week 6 for induction studies and clinical remission at week 44 for maintenance study. Results Percentage of patients achieving clinical response at week 6 was greater in ustekinumab 130 mg and ~6 mg/kg groups than in the placebo group (UNITI-1: 36.8% and 31.6% vs. 27.8%, respectively, for Japanese; 34.3% and 33.7% vs. 21.5%, respectively, for overall; UNITI-2: 37.5% and 55.6% vs. 11.1%, respectively, for Japanese; 51.7% and 55.5% vs. 28.7%, respectively, for overall). Clinical remission rate at week 44 during maintenance was greater in the ustekinumab 90 mg SC q12w and q8w groups than in the placebo group (50.0% and 55.6% vs. 25.0%, respectively, for Japanese; 48.8% and 53.1% vs. 35.9%, respectively, for overall). Efficacy and safety results observed in the Japanese subpopulation were generally consistent with those in the overall population. Conclusions Ustekinumab could be considered as a new therapeutic option for moderately to severely active CD in Japanese patients. Both ustekinumab induction and maintenance treatments were generally well tolerated (Clinical Trial Registration: NCT01369329, NCT01369342, NCT01369355).
Collapse
Affiliation(s)
- Toshifumi Hibi
- Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University, Tokyo, Japan
| | - Yuya Imai
- Janssen Pharmaceutical K.K., Tokyo, Japan
| | | | | | | | | |
Collapse
|
33
|
Hiramoto N, Takeda J, Yoshida K, Ono Y, Yoshioka S, Yamauchi N, Fujimoto A, Maruoka H, Shiraishi Y, Tanaka H, Chiba K, Imai Y, Miyano S, Ogawa S, Ishikawa T. Donor cell-derived transient abnormal myelopoiesis as a specific complication of umbilical cord blood transplantation. Bone Marrow Transplant 2017; 53:225-227. [PMID: 28991249 DOI: 10.1038/bmt.2017.226] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- N Hiramoto
- Department of Cell Therapy, Institute of Biomedical Research and Innovation, Kobe, Japan
| | - J Takeda
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - K Yoshida
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Y Ono
- Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan
| | - S Yoshioka
- Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan
| | - N Yamauchi
- Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan
| | - A Fujimoto
- Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan
| | - H Maruoka
- Department of Clinical Laboratory, Kobe City Medical Center General Hospital, Kobe, Japan
| | - Y Shiraishi
- Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - H Tanaka
- Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - K Chiba
- Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Y Imai
- Department of Clinical Pathology, Kobe City Medical Center General Hospital, Kobe, Japan
| | - S Miyano
- Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - S Ogawa
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - T Ishikawa
- Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan
| |
Collapse
|
34
|
Koinuma T, Mori A, Hatano T, Imai Y, Hattori N. Function analysis of c19orf12 by using a model of drosophila. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
35
|
Ishii J, Kawamoto M, Fujiwara S, Imai Y, Shishido-Hara Y, Nakamichi K, Saijo M, Takahashi K, Nukuzuma S, Kohara N. Punctate lesions demonstrated as an early sign of progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus: A clinico-pathological study. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
36
|
Kawachi H, Fujimoto D, Morimoto T, Ito M, Teraoka S, Sato Y, Nagata K, Nakagawa A, Otsuka K, Imai Y, Tomii K. Characteristics and prognostic impact of advanced non-small-cell lung cancer patients who were ineligible for clinical trials. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Sato T, Sato C, Kadowaki A, Watanabe H, Ho L, Ishida J, Yamaguchi T, Kimura A, Fukamizu A, Penninger J, Reversade B, Ito H, Imai Y, Kuba K. 5922A novel APJ ligand, ELABELA/Apela/Toddler, protects from pressure overload- and Angiotensin II-induced cardiac hypertrophy and fibrosis. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.5922] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Imai T, Ichimura M, Nakashima Y, Katanuma I, Yoshikawa M, Kariya T, Minami R, Miyata Y, Yamaguchi Y, Ikezoe R, Shimozuma T, Kubo S, Yoshimura Y, Takahashi H, Mutoh T, Sakamoto K, Mizuguchi M, Ota M, Ozawa H, Hosoi K, Yaguchi F, Yonenaga R, Imai Y, Murakani T, Yagi K, Nakamura T, Aoki1 H, Iizumi H, Ishii T, Kondou H, Takeda H, Ichioka N, Masaki S, Yokoyama T. Status and Plan of GAMMA 10 Tandem Mirror Program. Fusion Science and Technology 2017. [DOI: 10.13182/fst11-a11563] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Imai
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - M. Ichimura
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - Y. Nakashima
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - I. Katanuma
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - M. Yoshikawa
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Kariya
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - R. Minami
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - Y. Miyata
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - Y. Yamaguchi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - R. Ikezoe
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Shimozuma
- National Institute of Fusion Science(NIFS), Toki, Japan
| | - S. Kubo
- National Institute of Fusion Science(NIFS), Toki, Japan
| | - Y. Yoshimura
- National Institute of Fusion Science(NIFS), Toki, Japan
| | - H. Takahashi
- National Institute of Fusion Science(NIFS), Toki, Japan
| | - T. Mutoh
- National Institute of Fusion Science(NIFS), Toki, Japan
| | - K. Sakamoto
- Japan Atomic Energy Research Institute(JAEA), Naka, Japan
| | - M. Mizuguchi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - M. Ota
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - H. Ozawa
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - K. Hosoi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - F. Yaguchi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - R. Yonenaga
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - Y. Imai
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Murakani
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - K. Yagi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | | | - H. Aoki1
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - H. Iizumi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Ishii
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - H. Kondou
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - H. Takeda
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - N. Ichioka
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - S. Masaki
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Yokoyama
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | | |
Collapse
|
39
|
Ichimura M, Yamaguchi Y, Ikezoe R, Imai Y, Murakami T, Iwai T, Yokoyama T, Sato T, Ugajin Y, Imai T. Radial Transport of High-Energy Ions Caused by Low-Frequency Fluctuations in the GAMMA 10 Tandem Mirror. Fusion Science and Technology 2017. [DOI: 10.13182/fst11-a11583] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Ichimura
- Affiliation Information: Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - Y. Yamaguchi
- Affiliation Information: Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - R. Ikezoe
- Affiliation Information: Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - Y. Imai
- Affiliation Information: Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Murakami
- Affiliation Information: Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Iwai
- Affiliation Information: Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Yokoyama
- Affiliation Information: Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Sato
- Affiliation Information: Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - Y. Ugajin
- Affiliation Information: Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Imai
- Affiliation Information: Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| |
Collapse
|
40
|
Yamaguchi Y, Ichimura M, Yokoyama T, Fukuyama A, Ikezoe R, Imai Y, Murakami T, Iwai T, Sato T, Ugajin Y, Imai T. Ion-Cyclotron Resonance Heating Experiment in the Quadruple Minimum-B Field on GAMMA 10. Fusion Science and Technology 2017. [DOI: 10.13182/fst11-a11625] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Y. Yamaguchi
- Research Center for Development of Far-Infrared Region, University of Fukui, Fukui 910-8507, Japan
| | - M. Ichimura
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - T. Yokoyama
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - A. Fukuyama
- Department of Nuclear Engineering, Kyoto University, Kyoto 606-8501, Japan
| | - R. Ikezoe
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - Y. Imai
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - T. Murakami
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - T. Iwai
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - T. Sato
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - Y. Ugajin
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - T. Imai
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| |
Collapse
|
41
|
Ríos DB, Aulenbacher K, Baunack S, Diefenbach J, Gläser B, von Harrach D, Imai Y, Kabuß EM, Kothe R, Lee JH, Merkel H, Mora Espí MC, Müller U, Schilling E, Weinrich C, Capozza L, Maas FE, Arvieux J, El-Yakoubi MA, Frascaria R, Kunne R, Morlet M, Ong S, van de Wiele J, Kowalski S, Prok Y. New Measurements of the Beam Normal Spin Asymmetries at Large Backward Angles with Hydrogen and Deuterium Targets. Phys Rev Lett 2017; 119:012501. [PMID: 28731753 DOI: 10.1103/physrevlett.119.012501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/14/2016] [Indexed: 06/07/2023]
Abstract
New measurements of the beam normal single spin asymmetry in the electron elastic and quasielastic scattering on the proton and deuteron, respectively, at large backward angles and at ⟨Q^{2}⟩=0.22 (GeV/c)^{2} and ⟨Q^{2}⟩=0.35 ( GeV/c)^{2} are reported. The experimentally observed asymmetries are compared with the theoretical calculation of Pasquini and Vanderhaeghen [Phys. Rev. C 70, 045206 (2004).PRVCAN0556-281310.1103/PhysRevC.70.045206]. The agreement of the measurements with the theoretical calculations shows a dominance of the inelastic intermediate excited states of the nucleon, πN and the Δ resonance. The measurements explore a new, important parameter region of the exchanged virtual photon virtualities.
Collapse
Affiliation(s)
- D Balaguer Ríos
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - K Aulenbacher
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - S Baunack
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - J Diefenbach
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - B Gläser
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - D von Harrach
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - Y Imai
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - E-M Kabuß
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - R Kothe
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - J H Lee
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - H Merkel
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - M C Mora Espí
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - U Müller
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - E Schilling
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - C Weinrich
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
| | - L Capozza
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
- Helmholtz-Institut Mainz, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 36, D-55099 Mainz, Germany
| | - F E Maas
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 45, D-55099 Mainz, Germany
- Helmholtz-Institut Mainz, Johannes Gutenberg-Universität Mainz, J.J. Becherweg 36, D-55099 Mainz, Germany
| | - J Arvieux
- Institut de Physique Nucléaire, CNRS-IN2P3, Université Paris-Sud, F-91406 Orsay Cedex, France
| | - M A El-Yakoubi
- Institut de Physique Nucléaire, CNRS-IN2P3, Université Paris-Sud, F-91406 Orsay Cedex, France
| | - R Frascaria
- Institut de Physique Nucléaire, CNRS-IN2P3, Université Paris-Sud, F-91406 Orsay Cedex, France
| | - R Kunne
- Institut de Physique Nucléaire, CNRS-IN2P3, Université Paris-Sud, F-91406 Orsay Cedex, France
| | - M Morlet
- Institut de Physique Nucléaire, CNRS-IN2P3, Université Paris-Sud, F-91406 Orsay Cedex, France
| | - S Ong
- Institut de Physique Nucléaire, CNRS-IN2P3, Université Paris-Sud, F-91406 Orsay Cedex, France
| | - J van de Wiele
- Institut de Physique Nucléaire, CNRS-IN2P3, Université Paris-Sud, F-91406 Orsay Cedex, France
| | - S Kowalski
- Laboratory for Nuclear Science and Department of Physics, MIT, Cambridge, Massachusetts 02139, USA
| | - Y Prok
- Laboratory for Nuclear Science and Department of Physics, MIT, Cambridge, Massachusetts 02139, USA
| |
Collapse
|
42
|
Kabutoya T, Ishikawa S, Imai Y, Watanabe H, Kario K. P1801Polarity of atrial premature complexes predict stroke events in a community-dwelling population. Europace 2017. [DOI: 10.1093/ehjci/eux161.110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Kabutoya T, Imai Y, Watanabe H, Komori T, Mitsuhashi T, Kario K. P1748An increase of vectorcardiographic QRS area was associated with good prognosis in patients who underwent cardiac resynchronization therapy. Europace 2017. [DOI: 10.1093/ehjci/eux161.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Watanabe H, Kabutoya T, Satou A, Komori T, Imai Y, Kario K. P860The electrical conduction delay of the coronary sinus is associated with a large left atrial diameter in atrial fibrillation patients. Europace 2017. [DOI: 10.1093/ehjci/eux151.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
45
|
Hasegawa K, Matsushita H, Oda K, Yamamoto S, Nishijima A, Imai Y, Asada K, Ikeda Y, Fujiwara K, Aburatani H, Kakimi K. Immunoediting, neoantigen frequency, and clinical outcome in patients with ovarian clear cell carcinoma. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
46
|
Nagahori W, Kurebayashi E, Imai Y, Maeno T, Oguma Y, Iwakiri N, Suzuki M, Nagashima M, Yamashita T, Suzuki M. P1728Which is a better strategy in pulmonary vein isolation? Contiguous dragging versus point by point catheter ablation utilising tagging technology. Europace 2017. [DOI: 10.1093/ehjci/eux161.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
47
|
Imai Y, Watanabe H, Kabutoya T, Komori T, Watanabe T, Yokota A, Hachiya H, Kario K. P1805P wave vector electrography calculated from routine 12-lead ECG predicts recurrence of atrial fibrillation after pulmonary vein isolation. Europace 2017. [DOI: 10.1093/ehjci/eux161.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Hibi T, Imai Y, Senoo A, Ohta K, Ukyo Y. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study). J Gastroenterol 2017; 52:1101-1111. [PMID: 28324167 PMCID: PMC5606947 DOI: 10.1007/s00535-017-1326-1] [Citation(s) in RCA: 53] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Accepted: 02/25/2017] [Indexed: 02/04/2023]
Abstract
BACKGROUND The global phase 3 studies of golimumab [PURSUIT-SC and PURSUIT-maintenance (M)], an anti-tumor necrosis factor-α (anti-TNFα) antibody, have demonstrated clinical efficacy and safety as induction and maintenance therapies in patients with moderate to severely active ulcerative colitis (UC). This study aimed to evaluate the efficacy and safety of golimumab as maintenance therapy in the Japanese population. METHODS In this phase 3, double-blind (DB), placebo-controlled, parallel group, randomized withdrawal study, 144 Japanese patients with moderately to severely active UC received golimumab doses of 200 mg (at week 0) and 100 mg (at week 2) subcutaneously during the 6-week open-label induction phase. Patients who responded to golimumab induction therapy entered the DB maintenance (M) phase and were randomized (1:1) to receive 100 mg of golimumab subcutaneous injection (SC) or placebo every 4 weeks for 52 weeks. The primary endpoint was clinical response through M-week 54; secondary endpoints included clinical remission and mucosal healing at M-week 30 and 54. RESULTS Among induction responders, more patients on golimumab treatment (56.3%) maintained clinical response through M-week 54 versus the placebo group (19.4%). At both M-week 30 and 54, 50% golimumab-treated patients achieved clinical remission versus the placebo group (6.5%) and a higher proportion of patients on golimumab (59.4%) experienced mucosal healing than the placebo group (16.1%). Incidence of treatment-emergent adverse events was 96.9% in the golimumab group and 71% in the placebo group. Overall, the efficacy and safety results in this study were comparable with those observed in global studies. CONCLUSIONS Golimumab SC treatment maintained clinical efficacy through week 54 among induction responders, and no new safety signals were observed in the patients with moderate to severely active UC. CLINICAL TRIAL REGISTRATION The study is registered at ClinicalTrials.gov NCT01863771.
Collapse
Affiliation(s)
- Toshifumi Hibi
- Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8462 Japan
| | - Yuya Imai
- Janssen Pharmaceutical K.K., Tokyo, Japan
| | | | | | | |
Collapse
|
49
|
Matsumoto K, Tamura K, Yoshida H, Nishikawa T, Imai Y, Miyasaka A, Onoe T, Yamaguchi S, Shimizu C, Yonemori K, Shimoi T, Yunokawa M, Xiong H, Hashiba H, Kiriyama T, Leahy T, Shepherd S, Fujiwara K. A phase 1 study of single agent veliparib in Japanese subjects with advanced solid tumors. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw374.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
50
|
Hata A, Katakami N, Nanjo S, Okuda C, Kaji R, Masago K, Fujita S, Imai Y. Correlation between programmed death-ligand 1 (PD-L1) expression and T790M status in EGFR-mutant non-small cell lung cancer (NSCLC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|